This study demonstrates that the use of dissolving patches for insulin delivery achieves a satisfactory relative bioavailability (RBA) compared to conventional subcutaneous injection, demonstrating the effectiveness of dissolving patches for diabetes treatment [79]. The gene discussed is INS; the disease is diabetes mellitus.